Olema Pharmaceuticals, Inc. 8-K

What Happened

• Olema Pharmaceuticals (OLMA) filed an 8-K (Apr 29, 2026) announcing that the Board appointed Dr. Prakash Raman as a Class II director, effective April 28, 2026. His term runs through the Company’s annual meeting in 2028. The Board has determined Dr. Raman is an independent director under Nasdaq Rule 5605(a)(2). The Company also entered into its standard indemnification agreement with him.

Key Details

• Appointment effective date: April 28, 2026; term expires at 2028 annual meeting.
• Equity awards: nonstatutory stock option to purchase 24,150 shares (Initial Grant) vesting in 36 equal monthly installments over 3 years; nonstatutory option to purchase 2,911 shares (Partial Year Grant) vesting in full on June 11, 2026.
• Grants governed by the Company’s 2020 Equity Incentive Plan and related agreements.
• No arrangements or understandings with other persons regarding his selection and no related-party transactions required to be reported under Item 404(a).

Why It Matters

• Board composition and independence can affect corporate governance and oversight; adding an independent director may strengthen board expertise and committee makeup.
• The equity awards align Dr. Raman’s incentives with shareholders and tie his compensation to continued service through vesting dates.
• The filing is procedural (8-K Item 5.02) and does not report financial results or material transactions beyond the director appointment and customary compensation arrangements.